Charles Schwab Investment Management Inc Amylyx Pharmaceuticals, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 298,949 shares of AMLX stock, worth $1.12 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
298,949
Previous 302,270
1.1%
Holding current value
$1.12 Million
Previous $979,000
15.12%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding AMLX
# of Institutions
142Shares Held
49.1MCall Options Held
281KPut Options Held
438K-
Perceptive Advisors LLC New York, NY6.77MShares$25.3 Million0.85% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA4.64MShares$17.3 Million2.86% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.69MShares$10 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$9.96 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC2.43MShares$9.05 Million0.0% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $218M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...